Effect of thymosin α combined with piperacillin tazobactam compound on severe pneumonia and its influence on the changes of plasma PCT, hs CRP and sFTL-1 / 中国基层医药

ABSTRACT

Objective:To investigate the effect of thymosin α combined with piperacillin tazobactam compound in the treatment of severe pneumonia and its influence on the changes of plasma procalcitonin (PCT), high-sensitivity C-reactive protein (hs-CRP) and soluble vascular endothelial growth factor receptor 1 (sFTL-1).Methods:From January 2018 to December 2019, 118 patients with severe pneumonia admitted to the First People's Hospital of Jiande were randomly divided into observation group (59 cases) and control group (59 cases) according to random number table method.The control group was treated with piperacillin tazobactam compound, and the observation group was treated with thymosin α on the basis of the control group.The course of treatment in both two groups was 7 days.The therapeutic effect, APACHE Ⅱ score, blood gas analysis and changes of plasma PCT, hs-CRP and sFTL-1 were compared before and after treatment.Results:The total effective rate of the observation group (91.53%) was higher than that of the control group (74.58%) (χ 2=6.020, P<0.05). The APACHE Ⅱ score[(13.24±1.87)points] in the observation group was lower than that in the control group [(18.95±2.12)points]( t=15.515, P<0.05). The PaO 2[(75.46±3.28)mmHg] and PaO 2/FiO 2 (258.49±13.08) in the observation group were higher than those in the control group [(67.83±3.54)mmHg and (225.41±16.57)mmHg] ( t=12.144, 12.036, all P<0.05). The plasma levels of PCT [(4.23±0.78)μg/L], hs-CRP[(17.32±3.25)mg/L] and sFTL-1[(324.15±26.41)ng/L] in the observation group were lower than those in the control group [(7.59±1.42)μg/L, (32.14±7.28)mg/L and (394.21±24.09)ng/L] ( t=15.930, 14.278, 15.054, all P<0.05). Conclusion:Thymosin α combined with piperacillin tazobactam compound can significantly reduce the levels of PCT, hs-CRP and sFTL-1 in patients with severe pneumonia.